InFUSing antisense oligonucleotides for treating ALS
- PMID: 35246398
- DOI: 10.1016/j.molmed.2022.02.006
InFUSing antisense oligonucleotides for treating ALS
Abstract
The question of a loss or toxic gain of function in FUS-related amyotrophic lateral sclerosis is still debated. Recently, Korobeynikov et al. argued that FUS mutations lead to a gain of function and showed that lowering wild-type and mutant FUS levels could be a promising therapeutic strategy.
Trial registration: ClinicalTrials.gov NCT04768972.
Keywords: FUS; TDP-43; amyotrophic lateral sclerosis; antisense oligonucleotide.
Copyright © 2022 Elsevier Ltd. All rights reserved.
Comment on
-
Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis.Nat Med. 2022 Jan;28(1):104-116. doi: 10.1038/s41591-021-01615-z. Epub 2022 Jan 24. Nat Med. 2022. PMID: 35075293 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
